Johnson & Johnson Pharma Unit Plans To File More Than 10 New Products By 2019

(RTTNews) - Janssen Pharmaceutical Companies, the Pharmaceutical segment of Johnson & Johnson (JNJ), announced the company plans to file for regulatory approval of more than 10 new products between 2015 and 2019, each with the potential to exceed $1 billion in revenue, as well as more than 40 line extensions of existing and new medicines.

Janssen has launched 14 new products since 2009, seven of which already exceed or are on track to achieve sales in excess of $1 billion during 2015. The company said the combined strength of Janssen's in-market portfolio and robust near-term pipeline provides the momentum to sustain above-industry compound annual growth through 2019.